Short answer: Per the FDA label (2.2), Ozempic starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly. If more glycemic control is needed, the label's schedule allows 1 mg after at least 4 weeks on 0.5 mg, then 2 mg after at least 4 weeks on 1 mg. The maximum recommended dosage is 2 mg once weekly.
Per label section 1, Ozempic is indicated in adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control, to reduce the risk of major adverse cardiovascular events in those with established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in those with chronic kidney disease. This page summarizes the current FDA prescribing information (revised 5/2026). It is not personalized medical advice; your prescriber sets your dose.
The label's dosing schedule (label section 2.2):
| Period | Dose | Label note |
|---|---|---|
| Weeks 1–4 | 0.25 mg once weekly | Initiation dosage; the label says to follow the escalation to reduce the risk of gastrointestinal adverse reactions |
| Weeks 5–8 | 0.5 mg once weekly | Increase after 4 weeks on 0.25 mg; 0.5 mg is also one of the label maintenance dosages |
| Weeks 9–12 (earliest) | 1 mg once weekly | Only if additional glycemic control is needed, after at least 4 weeks on 0.5 mg; 1 mg is the label maintenance dosage for type 2 diabetes with chronic kidney disease |
| Week 13 onward (earliest) | 2 mg once weekly | Only if additional glycemic control is needed, after at least 4 weeks on 1 mg; maximum recommended dosage |
Maintenance: The label lists maintenance dosages of 0.5 mg, 1 mg, or 2 mg once weekly based on glycemic control, with a maximum recommended dosage of 2 mg once weekly. For type 2 diabetes with chronic kidney disease, the label maintenance dosage is 1 mg once weekly, reached after at least 4 weeks on 0.5 mg (2.2).
Below is the label schedule laid out week by week, using the earliest timing the label allows. The label lets prescribers stay at a step longer, so a real calendar is often slower. The blank columns are for your own record.
| Week | Label dose | Date | Site / time | Weight | Notes |
|---|---|---|---|---|---|
| Week 1 | 0.25 mg once weekly | ||||
| Week 2 | 0.25 mg once weekly | ||||
| Week 3 | 0.25 mg once weekly | ||||
| Week 4 | 0.25 mg once weekly | ||||
| Week 5 | 0.5 mg once weekly | ||||
| Week 6 | 0.5 mg once weekly | ||||
| Week 7 | 0.5 mg once weekly | ||||
| Week 8 | 0.5 mg once weekly | ||||
| Week 9 | 1 mg once weekly | ||||
| Week 10 | 1 mg once weekly | ||||
| Week 11 | 1 mg once weekly | ||||
| Week 12 | 1 mg once weekly | ||||
| Week 13 | 2 mg once weekly | ||||
| Week 14 | 2 mg once weekly | ||||
| Week 15 | 2 mg once weekly | ||||
| Week 16 | 2 mg once weekly | ||||
| Week 17 | 2 mg once weekly | ||||
| Week 18 | 2 mg once weekly | ||||
| Week 19 | 2 mg once weekly | ||||
| Week 20 | 2 mg once weekly |
Printing this page prints the schedule and calendar without the site navigation.
| Product | Dose per injection | Doses per pen / pack | Contents |
|---|---|---|---|
| Single-patient-use pen | 0.25 mg or 0.5 mg | 4 doses of 0.25 mg and 2 doses of 0.5 mg, or 4 doses of 0.5 mg (carton: 1 pen, 6 NovoFine Plus needles) | 2 mg/3 mL (0.68 mg/mL) |
| Single-patient-use pen | 1 mg | 4 doses of 1 mg (carton: 1 pen, 4 NovoFine Plus needles) | 4 mg/3 mL (1.34 mg/mL) |
| Single-patient-use pen | 2 mg | 4 doses of 2 mg (carton: 1 pen, 4 NovoFine Plus needles) | 8 mg/3 mL (2.68 mg/mL) |
| Single-dose prefilled syringe | 0.25 mg | 1 dose per syringe (carton: 4 syringes) | 0.25 mg/0.5 mL |
| Single-dose prefilled syringe | 0.5 mg | 1 dose per syringe (carton: 4 syringes) | 0.5 mg/0.5 mL |
| Single-dose prefilled syringe | 1 mg | 1 dose per syringe (carton: 4 syringes) | 1 mg/0.5 mL |
The label reports these rates from placebo-controlled trials (label section 6.1, Table 1). Percentages are the share of trial participants who reported each reaction.
| Adverse reaction | Placebo (N=262) | Ozempic 0.5 mg (N=260) | Ozempic 1 mg (N=261) |
|---|---|---|---|
| Nausea | 6.1% | 15.8% | 20.3% |
| Vomiting | 2.3% | 5% | 9.2% |
| Diarrhea | 1.9% | 8.5% | 8.8% |
| Abdominal pain | 4.6% | 7.3% | 5.7% |
| Constipation | 1.5% | 5% | 3.1% |
When do they happen? Per the label, the majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. Gastrointestinal adverse reactions overall occurred in 15.3% (placebo), 32.7% (0.5 mg), and 36.4% (1 mg); in the 1 mg vs 2 mg trial they occurred in 30.8% (1 mg) and 34% (2 mg) (6.1).
The label also carries warnings that are not in this table (for example, a boxed warning or pancreatitis and gallbladder warnings where applicable). Read the full label linked under Sources, and report side effects to your prescriber.
Per the label, a missed dose is given as soon as possible within 5 days after the missed dose; if more than 5 days have passed, the missed dose is skipped and the next dose is given on the regularly scheduled day, after which the regular once-weekly schedule resumes. (label section 2.1) The full walk-through is on the Ozempic missed-dose page.
The label describes once-weekly subcutaneous injection on the same day each week, at any time of day, with or without meals, in the abdomen, thigh, or upper arm, using a different injection site each week within the same region. The weekly day can be changed if at least 2 days (more than 48 hours) separate two doses. With insulin, the label describes separate, non-adjacent injections that are never mixed. (label section 2.1)
A simple log makes each titration step easier to talk through with your prescriber. These are the things worth writing down, and how Dose Track handles them:
Your log stays on your phone. See GLP-1 tracking in Dose Track for the full feature list.
Reviewed as of . Section numbers above refer to the FDA prescribing information.
All GLP-1 brand guides · GLP-1 tracking · Supported medications